COVID-19 - Inpatient
Community-Acquired Pneumonia (CAP)

Community-Acquired Pneumonia (CAP)

Clinical Considerations

Scripps local data suggests low incidence of MRSA (3%) and Pseudomonas aeruginosa (3%)

Routine anaerobic coverage not indicated unless empyema or abscess

Blood and sputum cultures should be ordered when considering broad spectrum coverage against MRSA and P. aeruginosa

  • De-escalate antibiotics if MRSA/P. aeruginosa not isolated at 48-72 hours
  • Negative MRSA nasal cultures can be used to de-escalate anti-MRSA therapy

More Information

Metlay J et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. Am J Respir Crit Care Med. 2019;200(7):e45-67.